Wedbush Maintains Outperform on Immunome, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 90.0%

Neg 0% Neu 0% Pos 90%

Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.